Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study

Table 3

Mean extraction recovery and matrix effects of anlotinib and the IS in rat plasma (n = 6).

Compound	Concentration (ng/mL)	Extraction recoveries (%)		Matrix effects (%)
		Mean ± SD	RSD (%)	Mean ± SD	RSD (%)
Anlotinib	0.25	99.32 ± 6.74	6.79	104.27 ± 3.65	3.51
	5	102.27 ± 6.48	6.33	102.42 ± 4.17	4.07
IS	40	104.14 ± 3.95	3.8	101.33 ± 4.08	4.03
	100	106.09 ± 8.11	7.65	101.66 ± 4.53	4.45